We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Abbott Diagnostics

Abbott Diagnostics provides medical diagnostic instruments, tests, automation and informatics solutions, including cl... read more Featured Products: More products

Download Mobile App




C. Diff Carriers Are Source of Infections in Hospitals

By LabMedica International staff writers
Posted on 26 Dec 2019
Clostridioides difficile is a spore-forming, gram-positive anaerobic bacillus spread by fecal–oral transmission of spores, which remain viable for long periods of time ex vivo. More...
Although C. difficile carriers do not have diarrhea, they do shed spores that can contaminate environmental surfaces.

Annually, there are more than 400,000 cases and almost 30,000 deaths from C.difficile–associated diarrhea occur in the USA. Efforts to reduce the spread of C. difficile have focused on reducing transmission from patients with symptomatic C. difficile–associated diarrhea. Asymptomatic carriers may serve as a reservoir and spread C. difficile to those around them.

Medical scientists associated with the Montefiore Medical Center (The Bronx, NY, USA) performed a prospective cohort study on a sample of patients being admitted to a large university hospital between July 2017 and March 2018. The team tested 220 patients who showed no symptoms of C. difficile infection when they were admitted. Perirectal swabs (Copan Diagnostics, Murrieta, CA, USA) were completed within 24 hours of admission, and the patients were followed for six months.

Two testing methodologies were used for all specimens: C. difficile Quik Chek Complete (Abbott, Chicago, IL, USA) to test for glutamate dehydrogenase (GDH) and toxins A and B and XPert C. difficile/Epi (Cepheid, Sunnyvale, CA, USA) real-time polymerase chain reaction (PCR) assay that detects the toxin B gene. All specimens were also tested by toxigenic culture using spore-enriched specimens in cultures with selective chopped meat broth incubated for 48–72 hours followed by repeat GDH and toxin A/B testing.

The scientists reported that of the 220 subjects, 21 (9.6%) were C. difficile carriers, including 10.2% of the nursing facility residents and 7.7% of the community residents. Among the 21 C. difficile carriers, eight (38.1%) progressed to symptomatic C. difficile, but only four (2.0%) of the 199 non-carriers progressed to symptomatic C. difficile.

The authors concluded that asymptomatic carriers may represent a significant reservoir for transmission of C. difficile, and progression from asymptomatic carriage to symptomatic C. difficile infection (CDI) may account for a significant proportion of CDI that is classified as “healthcare-facility onset.” Therefore, identification of asymptomatic carriers could reduce the spread of C. difficile. Specific environmental, isolation, and stewardship strategies to prevent spread of C. difficile from carriers to uninfected patients as well as prevent progression to symptomatic CDI warrant further study.

Sarah Baron, MD, MS, an Assistant Professor of Medicine and lead author of the study, said, “It has generally been assumed that patients get the bacteria during their stay in the hospital. However, when we tested patients being admitted to the hospital, we found that many of them were carrying the bacteria that cause this diarrhea in their bodies already and often went on to develop the infection.” The study was published on December 11, 2019 in the journal Infection Control & Hospital Epidemiology.

Related Links:
Montefiore Medical Center
Copan Diagnostics
Abbott
Cepheid



Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Aspiration System
VACUSAFE
New
Gastrointestinal Panel
Xpert® GI Panel
Immunofluorescence Analyzer
IFA System
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: LVOne uses blood-based biomarkers to detect stroke and identify large vessel occlusion before hospital arrival, providing objective results earlier than traditional assessments. (Photo courtesy of UpFront Diagnostics)

First-of-Its-Kind Rapid Blood Test Gains CE Mark to Support Prehospital Stroke Triage

Rapid stroke identification before hospital arrival is critical because treatment efficacy declines with every minute of delay. However, definitive assessment typically requires hospital-based imaging,... Read more

Molecular Diagnostics

view channel
Image: Graphical Abstract (Image Credit: Cheng N, Ouellette TW, Skead K, et al. Pre-diagnosis plasma cell-free DNA reveals early signatures of prostate and breast cancer risk up to eight years prior to clinical detection. Cell Genomics (2026). DOI:10.1016/j.xgen.2026.101364)

Blood Test Stratifies Prostate and Breast Cancer Risk Years Before Diagnosis

Cancer is the second leading cause of death globally, and late diagnosis contributes substantially to mortality. Routine screening is available for only a few cancer types, while other early detection... Read more

Immunology

view channel
Image: Aptiva utilizes particle-based multi-analyte technology (PMAT) (Photo courtesy of Werfen)

Werfen Expands Automated APS Testing with FDA-Cleared and CE-Marked IgA Reagent

Antiphospholipid syndrome (APS) is an autoimmune disorder associated with thrombosis and pregnancy complications, but its symptoms can overlap with those of other conditions, complicating diagnosis.... Read more

Technology

view channel
Image: ADLM recommends that emerging AI tools follow the same professional oversight, quality, validation, and monitoring standards as traditional clinical testing within CLIA’s existing framework (Image Credit: Adobe Stock)

ADLM Calls for CLIA Updates to Support Safe AI Use in Laboratory Medicine

Clinical laboratories increasingly use artificial intelligence to verify, interpret, and report results, but safeguards under the Clinical Laboratory Improvement Amendments (CLIA) were designed in 1992.... Read more

Industry

view channel
Image: Collaboration combines cognitive assessment, blood testing, phlebotomy, and MRI to support faster diagnosis across the UK (Image Credt: Adobe Stock)

New UK Collaboration Expands Access to Integrated Alzheimer’s Diagnostic Testing

C2N Diagnostics and Cambridge Cognition have partnered with The Alzheimer’s Trust to create an integrated pathway aimed at supporting earlier and more accurate diagnosis of Alzheimer’s disease and related dementias.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.